ArticleOncotarget2017
Efficacy and safety of Apatinib in stage IV sarcomas: experience of a major sarcoma center in China.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of apatinib in the treatment of osteosarcoma: a single-arm meta-analysis among Chinese patients.BMC cancer · 2021Pooled it
- Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy.Cancer biology & medicine · 2020Trial
- Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial.The oncologist · 2019Trial
- Osteosarcoma as a communication-driven disease: redefining tumor-bone signaling networks as therapeutic targets.Frontiers in oncology · 2026Review
- Ovarian Angiosarcoma With Intractable Intraperitoneal Hemorrhage: A Case Report and Review of the Literature.Cureus · 2025Article
- Malignant gastrointestinal neuroectodermal tumor: a case report and literature review.Annals of medicine and surgery (2012) · 2023Article
- Regorafenib for the Treatment of Sarcoma.Current treatment options in oncology · 2022Review
- Efficacy and safety of apatinib in advanced refractory soft tissue sarcoma and association with histologic subtypes: a multicenter retrospective study.Annals of translational medicine · 2022Article
- Effective Treatment of Low-Grade Myofibroblastic Sarcoma with Apatinib: A Case Report and Literature Review.Pharmacogenomics and personalized medicine · 2022Article
- Apatinib Functioned as Tumor Suppressor of Synovial Sarcoma through Regulating miR-34a-5p/HOXA13 Axis.Computational and mathematical methods in medicine · 2022Article
- Retrospective Review of Efficacy and Safety of Anlotinib in Advanced Leiomyosarcoma: A Real-World Study.Cancer management and research · 2022Article
- Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression.Journal of ovarian research · 2021Article
- Apatinib suppresses the migration, invasion and angiogenesis of hepatocellular carcinoma cells by blocking VEGF and PI3K/AKT signaling pathways.Molecular medicine reports · 2021Article
- Apatinib treatment is effective for metastatic malignant phyllodes tumors of the breast: a case report.BMC women's health · 2021Article
- Targeting the VEGF Pathway in Osteosarcoma.Cells · 2021Review
- Safety of apatinib plus S-1 for advanced solid tumor as palliative treatment.Experimental and therapeutic medicine · 2021Article
- Clinical response and safety of apatinib monotherapy in recurrent, metastatic cervical cancer after failure of chemotherapy: a retrospective study.Journal of gynecologic oncology · 2020Article
- Apatinib Mesylate Inhibits the Proliferation and Metastasis of Epithelioid Malignant Peritoneal MesotheliomaFrontiers in oncology · 2020Article
- Raltitrexed Enhances the Antitumor Effect of Apatinib in Human Esophageal Squamous Carcinoma Cells via Akt and Erk Pathways.OncoTargets and therapy · 2020Article
- Efficacy and Safety of Apatinib in the Treatment of Postoperative Recurrence of Fibrosarcoma.OncoTargets and therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study was conducted to review the efficacy and safety of Apatinib in stage IV sarcoma patients who failed previous chemotherapy. MATERIALS AND
methodsThe clinical information on 16 patients with stage IV sarcomas who failed in prior chemotherapy and subsequently received Apatinib treatment was collected. Apatinib was given 500mg/daily and 4 weeks as a cycle. All patients had at least one measurable extracranial tumor according to Response Evaluation Criteria In Solid Tumors 1.0 criteria. Progression free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR) and treatment-related adverse effects (AEs) were reviewed and evaluated.
resultsPatients was administered Apatinib for 0 to 9 cycles with the median of 3.2 cycles. Median follow-up time was 8.4 months (1 to 12 months). Ten of 16 patients received at least 1 complete cycle of Apatinib treatment were eligible for the efficacy analysis. The median PFS was 8.84 months. Two patients achieved partial response (PR) and 6 patients achieved stable disease (SD). Two patients were evaluated as progression disease (PD) and one patient died of disease progression. The ORR was 20.0% (2/10) and the DCR was 80.0% (8/10). The most common grade 3/4 treatment-related AEs were hypertension (18.7%), hand-foot syndrome (12.5%) and proteinuria (6.3%). No drug-related severe AEs occurred.
conclusionCApatinib treatment in this exploratory study exhibited objective efficacy and manageable toxicity in stage IV sarcoma patients who failed in chemotherapy. This result supports future random controlled trial to further define Apatinib activity in stage IV sarcomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.